Jasper Therapeutics secures $132 million and merges with Kira Pharmaceuticals to revive pipeline

Jasper Therapeutics, a cash‑strapped biotech, announced it completed an all‑stock acquisition of privately held immune‑drug developer Kira Pharmaceuticals.

The merger is paired with a private stock offering that raised $132 million, giving Jasper enough cash to fund operations through the second half of 2028 after reporting just $14 million at the end of March.

The combined company will keep the Jasper ticker and add Kira’s two immune‑disease candidates to its pipeline, while Jasper continues to develop its experimental antibody briquilimab for chronic urticaria.

The deal follows recent setbacks that forced Jasper to lay off half its staff, halt other research programs, and see its chief medical officer depart.